Neurodegeneration in multiple sclerosis
GM Mey, KR Mahajan… - WIREs mechanisms of …, 2023 - Wiley Online Library
Axonal loss in multiple sclerosis (MS) is a key component of disease progression and
permanent neurologic disability. MS is a heterogeneous demyelinating and …
permanent neurologic disability. MS is a heterogeneous demyelinating and …
Utility of the visual system to monitor neurodegeneration in multiple sclerosis
GM Mey, TM DeSilva - Frontiers in Molecular Neuroscience, 2023 - frontiersin.org
Neurodegeneration occurs early in the multiple sclerosis (MS) disease course and is an
important driver of permanent disability. Current immunomodulatory therapies do not directly …
important driver of permanent disability. Current immunomodulatory therapies do not directly …
3-Dimensional Immunostaining and Automated Deep-Learning Based Analysis of Nerve Degeneration
Multiple sclerosis (MS) is an autoimmune and neurodegenerative disease driven by
inflammation and demyelination in the brain, spinal cord, and optic nerve. Optic neuritis …
inflammation and demyelination in the brain, spinal cord, and optic nerve. Optic neuritis …
Sub-clinical glutamate receptor antagonist combinations prevent progressive demyelination.
V Mitchener, C Bulman, A Mellor, N Bhatt, B Alghamdi… - bioRxiv, 2024 - biorxiv.org
Multiple sclerosis (MS) affects almost 3 million people globally who suffer demyelination as
a series of relapses and remissions that tend towards progressive deterioration over time …
a series of relapses and remissions that tend towards progressive deterioration over time …
Utilizing the Visual System to Evaluate the Role of Demyelination and Axonal Injury in Neurodegeneration during Multiple Sclerosis
GM Mey - 2023 - rave.ohiolink.edu
Multiple sclerosis (MS) is a demyelinating and neurodegenerative disease affecting 2.5
million people globally. Immunomodulatory therapies reduce central nervous system (CNS) …
million people globally. Immunomodulatory therapies reduce central nervous system (CNS) …